



Parion Sciences Reacquires Rights to Epithelial Sodium Channel Inhibitors

Durham, NC (January 23, 2020) – Parion Sciences, a company dedicated to the development of novel treatments for pulmonary diseases, announced today that it has reached an agreement with Vertex Pharmaceuticals, Inc. to reacquire the pulmonary rights to epithelial sodium channel (ENaC) inhibitors developed under a collaboration announced between the parties in 2015. Under this agreement, Vertex is eligible to receive future undisclosed royalties based upon commercial success.

During their collaboration, the companies evaluated P-1037/VX-371 in multiple Phase 2 clinical studies as a potential treatment for cystic fibrosis and primary ciliary dyskinesia patients. In clinical studies, P-1037/VX-371 was generally well tolerated.

“Parion appreciates Vertex’s support over the course of our collaboration by progressing P-1037 into multiple patient populations.” said Paul Boucher, President, Parion Sciences. “At this time, Parion is evaluating scenarios for P-1037’s continued development as a potential therapy treating those patients who suffer from diseases as a result of mucus obstruction.”

About ENaC Inhibitors and P-1037

Epithelial sodium channel (ENaC) inhibitors are designed to block the sodium channels on the airway surfaces. In pulmonary diseases, such as chronic obstructive pulmonary disease, cystic fibrosis and primary ciliary dyskinesia, where there is a build-up of excessively concentrated mucus, preclinical models have demonstrated that blocking ENaC hydrates the mucus on the lung surface. Hydration of airway mucus restores airway clearance and improves lung function. P-1037 is a novel, long acting ENaC Inhibitor that was well tolerated at the doses tested in multiple clinical trials in healthy volunteers and patients with either cystic fibrosis or primary ciliary dyskinesia.

About Parion Sciences

Parion Sciences is a development stage biopharmaceutical company dedicated to research, development and commercialization of treatments to improve and extend the lives of patients with innate mucosal surface defense deficiencies of the airways. Parion has a diverse pipeline of pre-clinical and clinical candidates for the treatment of these diseases via distinctive mechanisms of action and approaches. Parion is at the forefront of ENaC development and is leveraging our scientific expertise in epithelial biology to expand our platforms and novel chemical compounds into new indications to treat mucosal defects. Parion has received support and grant funding from the National Institutes of Health and the Cystic Fibrosis

Foundation Therapeutics, Inc. For more information, please see our website at www.Parion.com.

For further information please contact:

Paul Boucher
President & CEO
Parion Sciences, Inc.
pboucher@parion.com
(919) 313-1195